Results 51 to 60 of about 2,235,192 (340)

Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association

Circulation: Arrhythmia and Electrophysiology, 2021
Atrial fibrillation and heart failure with reduced ejection fraction are increasing in prevalence worldwide. Atrial fibrillation can precipitate and can be a consequence of heart failure with reduced ejection fraction and cardiomyopathy.
Rakesh Gopinathannair, L. Chen, M. Chung, W. Cornwell, K. Furie, Dhanunjaya R. Lakkireddy, N. Marrouche, A. Natale, B. Olshansky, J. Joglar   +9 more
semanticscholar   +1 more source

The Gut Microbiome of Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
Background Risk factors for heart failure with preserved ejection fraction (HFpEF) include hypertension, age, sex, and obesity. Emerging evidence suggests that the gut microbiota independently contributes to each one of these risk factors, potentially ...
A. Beale, J. O’Donnell, M. Nakai, S. Nanayakkara, D. Vizi, K. Carter, E. Dean, R. Ribeiro, S. Yiallourou, M. Carrington, F. Marques, D. Kaye   +11 more
semanticscholar   +1 more source

Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial

Cardiovascular Diabetology
Background Clinical trials have established the prognostic benefits of sodium‒glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and heart failure (HF) with preserved ejection fraction (HFpEF), although the ...
Artem Ovchinnikov, Alexandra Potekhina, Anastasiia Filatova, Olga Svirida, Kristina Zherebchikova, Fail Ageev, Evgeny Belyavskiy   +6 more
doaj   +1 more source

Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies.

Annual Review of Medicine, 2021
Approximately half of all patients with heart failure (HF) have a preserved ejection fraction, and the prevalence is growing rapidly given the aging population in many countries and the rising prevalence of obesity, diabetes, and hypertension. Functional
K. Omote, F. Verbrugge, B. Borlaug
semanticscholar   +1 more source

Conserved structural motifs in PAS, LOV, and CRY proteins regulate circadian rhythms and are therapeutic targets

FEBS Letters, EarlyView.
Cryptochrome and PAS/LOV proteins play intricate roles in circadian clocks where they act as both sensors and mediators of protein–protein interactions. Their ubiquitous presence in signaling networks has positioned them as targets for small‐molecule therapeutics. This review provides a structural introduction to these protein families.
Eric D. Brinckman, Anna E. Lester, Brian D. Zoltowski   +2 more
wiley   +1 more source

Heart Failure With Recovered Ejection Fraction

Journal of the American College of Cardiology, 2018
Recently, the term heart failure (HF) with recovered ejection fraction (HFrecovEF) was introduced for patients with a normalization of the left ventricular ejection fraction (LVEF) [(1)][1].
Merken, Jort, Brunner-La Rocca, Hans-Peter, Weerts, Jerremy, Verdonschot, Job, Hazebroek, Mark, Schummers, Georg, Schreckenberg, Marcus, Lumens, Joost, Heymans, Stephane, Knackstedt, Christian   +9 more
openaire   +2 more sources

Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.

JAMA cardiology, 2021
Importance Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in patients with heart failure and a reduced ejection fraction (HFrEF). The association with cardiac remodeling has not been investigated.
M. Omar, J. Jensen, Mulham Ali, P. Frederiksen, C. Kistorp, L. Videbæk, M. Poulsen, C. Tuxen, S. Möller, F. Gustafsson, L. Køber, M. Schou, J. Møller   +12 more
semanticscholar   +1 more source

In situ molecular organization and heterogeneity of the Legionella Dot/Icm T4SS

FEBS Letters, EarlyView.
We present a nearly complete in situ model of the Legionella Dot/Icm type IV secretion system, revealing its central secretion channel and identifying new components. Using cryo‐electron tomography with AI‐based modeling, our work highlights the structure, variability, and mechanism of this complex nanomachine, advancing understanding of bacterial ...
Przemysław Dutka, Yuxi Liu, Stefano Maggi, Debnath Ghosal, Jue Wang, Prashant P. Damke, Stephen D. Carter, Wei Zhao, Sukhithasri Vijayrajratnam, Joseph P. Vogel, Carrie L. Shaffer, Grant J. Jensen   +11 more
wiley   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Mycobacterial cell division arrest and smooth‐to‐rough envelope transition using CRISPRi‐mediated genetic repression systems

FEBS Open Bio, EarlyView.
CRISPRI‐mediated gene silencing and phenotypic exploration in nontuberculous mycobacteria. In this Research Protocol, we describe approaches to control, monitor, and quantitatively assess CRISPRI‐mediated gene silencing in M. smegmatis and M. abscessus model organisms.
Vanessa Point, Wafaa Achache, Janïs Laudouze, Eliana Sepulveda Ramos, Mickaël Maziero, Céline Crauste, Stéphane Canaan, Pierre Santucci   +7 more
wiley   +1 more source